News

Graybug Vision’s Phase 2b ALTISSIMO trial of GB-102 focuses on the treatment of wet age-related macular degeneration.

Findings from retrospective study support intraoperative cefuroxime irrigation.

Joseph Grieco, PhD, notes that treatment fills a gap for patients who are unresponsive to the standard treatments for noninfectious keratitis.

Ocular Innovations debuts an option that delivers content touchpoints through a frictionless mobile experience.

Tarsus Pharmaceuticals kicks off Saturn-2, trial, which is designed similar to Saturn-1, first pivotal trial for TP-03. Topline data from Saturn-1 is expected in July.

According to Applied Genetic Technologies Corp., groups 5 and 6 had a 50% response rate among patients who met the inclusion criteria for the Skyline and Vista trials.

According to Lloyd Paul Aiello, MD, PhD, a key hurdle for diabetic retinopathy is the lack of patient awareness, which is a substantial contributor to non-adherence to eye care guidelines and poor outcomes.

According to Sandoz, it will begin enrolling the first patients in MYLIGHT, a clinical Phase III confirmatory efficacy and safety study.

Logan Vander Woude, DO, MPH, examines research on improved resolution of symptomatic vitreomacular traction as an attempt to further refine the potential factors predictive of better outcomes.

After more than a decade at the helm of the American Academy of Ophthalmology as its CEO, David W. Parke II, MD, has announced that he will be stepping down from the position.

After receiving FDA approval for its IPL device, Lumenis Ltd. announced that it is launching OptiLight, a bright solution for dry eyes.

Johnson & Johnson Vision announced today that the FDA has granted 510(k) clearance and CE mark for its VERTIAST Vision System, a next-generation phacoemulsification innovation.

ThermaMEDx has unveiled a self-heating, pre-moistened, disposable, sterile cleaning eye-pad for use in treating the symptoms of dry eyes and meibomian gland dysfunction.

George Waring IV, MD serves as guest host for ‘History and Evolution of Contemporary Refractive Surgery’

The National Institute of Health has supported early testing of the artificial retina. Now, scientists are testing whether manufacturing it on the International Space Station results in a viable treatment for people with blinding eye diseases.

Bausch + Lomb and Novaliq GmbH have announced statistically significant topline data from the first phase 3 trial analyzing the investigational drug NOV03 as a first-in-class eye drop to treat dry eye disease associated with MGD.

‘Revolutionary Eye and Vision Research’ theme of annual meeting.

Santen, Massachusetts Eye and Ear, Ulster University researchers will focus on ways to preserve vision by slowing, reversing, or preventing the damage.

Ocuphire Pharma’s ZETA-1 trial will investigate the potential of APX3330 to offer an oral treatment for diabetic retinopathy.

A diminishment of both hearing and vision is linked to an increased risk for dementia and mental decline, according to a new study.

Bausch + Lomb’s ClearVisc dispersive ophthalmic viscosurgical device has received FDA approval for use in ophthalmic surgery.

According to Verizon Business, BlueJeans Telehealth is way for providers and patients to conduct data-driven virtual care conversations.

During the trial, a patient gained vision, which lasted more than a year, after a single injection of an experimental RNA therapy into the eye.

The American Academy of Ophthalmology’s Truhlsen-Marmor Museum of the Eye is offering a free 2-part virtual series that will provide attendees an idea what is going on inside of their very own eyes and gut.

Drinking alcohol on a regular basis may decrease patients’ chances of developing cataracts that require surgery, new research shows.

Doug Mastel, who founded Mastel Precision Surgical Instruments Inc., passed away on March 20. He was 67.

A decision to stop the trial is based on results of a pre-planned interim sample size analysis conducted by an independent committee.

Clinical-stage pharma company announces next step in investigation of BRIMOCHOL to treat presbyopia.

ProQR Therapeutics has unveiled the results from its Phase 1/2 Stellar trial examining QR-421a n patients with Usher syndrome and non-syndromic retinitis pigmentosa.

A clinical trial of NCX 470 will evaluate the drug for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension.